Drug residues store in the body following cessation of use: Impacts on neuroendocrine balance and behavior – Use of the Hubbard sauna regimen to remove toxins and restore health

https://doi.org/10.1016/j.mehy.2006.08.035Get rights and content

Summary

For decades, scientists have investigated the environmental and human health effects of synthetic chemicals. A growing body of research has illuminated the spectrum of consequences deriving from our reliance these substances and their proliferation in air, water, soil and the food chain. Of particular concern is the fact that residues of many man-made chemicals are now detectible in virtually every person. A key to a chemical’s tendency to persist in tissues once it has entered the body is its lipophilicity. Substances that are poorly soluble in water and quite soluble in fat have relatively free access, via lipid-rich cellular membranes, to the cells of all organs including the ability to cross the blood–brain and placental barriers. Substantial data exist demonstrating that in addition to pollutants, drugs and their metabolites dispose to tissues high in fat content, including brain and adipose. While their characteristic lipophilicity permits drugs and medications to reach target tissues, thereby producing therapeutic effects in the present, current perceptions of risk may be ignoring the possibility that adipose accumulations of illicit drugs and pharmaceuticals may lead to future patterns of ill health similar to those associated with exposure to other categories of xenobiotic chemicals. Empirical data are beginning to characterize the myriad regulatory functions of adipose hormones, including roles in cravings, cognitive function, energy level, and inflammation as well as changes in adipose hormone levels associated with drug use. Included in this data are the observation that a rehabilitative treatment intervention introduced by L. Ron Hubbard in 1978 to aid in the broad elimination of chemicals from body stores improves symptoms common to both chemical exposure and drug addiction. The regimen, which includes exercise, sauna bathing, and vitamin and mineral supplementation, is utilized by nearly 70 drug rehabilitation and medical practices in over 20 countries. At present, much more is unknown than is known regarding long-term drug retention and effects. This subject deserves careful evaluation given its potential implications for health and chronic illnesses of poorly defined etiology (such as chronic fatigue syndrome), as well as drug abuse prevention, drug rehabilitation, forensic and legal areas.

Introduction

Research now reveals detectible levels of human-manufactured toxins in all individuals. One study alone found 167 different contaminants in volunteers who did not work with chemicals or near industrial facilities [1].

Accumulations of chemicals in body tissues are increasingly associated with patterns of adverse health including suppressed or inappropriate/hyperreactive immune function (autoimmunity, asthma, allergies), cancers, cognitive deficits, mood changes, neurological illnesses, changes in libido, reproductive dysfunction, and glucose dysregulation [2], [3]. There is even concern that pregnant women exposed to toxins can pass disorders on to their children – even for several succeeding generations [4].

While policy initiatives such as the European REACH (the name REACH refers to its three key steps: Registration, Evaluation and Authorization of Chemicals) appropriately trigger an authorization process to regulate environmental chemicals exhibiting certain hazardous characteristics considered of “very high concern” – such as persistent bioaccumulative toxics and endocrine-disrupting chemicals – it is noteworthy that chemicals classified as “pharmaceuticals” have many similar characteristics but are not addressed with the same caution as environmental chemicals. Environmental chemicals with bioaccumaltive tendencies are avoided for their potential to cause adverse health, while the use of nonbiological drugs that may have comparable persistence is generally encouraged.

Although these categories of compounds are given different names and are differentially regulated by law, are they really so different? Perhaps, emerging research argues, addictive and avoidant individual behaviors are simply different responses to the same underlying mechanism [5].

Within the spectrum of these chemicals, the key to their similarity is lipophilicity – the tendency of a compound to diffuse into lipid-rich spaces. Many of these substances are poorly soluble in water and quite soluble in fat, including the white adipose tissue and all cellular membranes – thereby giving them relatively free access to the cells of all organs, body wide. Hence, long-term storage, both within adipose and elsewhere, and the possibility that these chemicals may contribute to a cumulative toxic burden, are important issues.

Tests to determine chemical safety and consequent health impacts do not take into account combinations of contaminants; thus, effects are largely underestimated or potentially unobserved. A single perturbation may not appear to shift the dynamic system, but with each additional perturbation an instability is added, capable at some point of tipping the balance between states described as “health” and “illness.”

There are many mechanisms by which retention in the body can negatively impact health.

Many drugs and toxins mimic substances naturally found in the body and may directly affect normal trans-cellular chemical communication by hormones and cytokines1 – such structural mimetics often causing effects quite dissimilar or even opposite to those of the endogenous substance (for example blockage of a receptor normally accessible to a hormone). This may occur locally within a tissue (paracrinely), or endocrinely as drugs/toxins are released from body tissues back into circulation. Further, circulating drugs and toxins may occupy sites on plasma transport proteins thereby subtly interfering with the equilibria kinetics that govern plasma transport of nutrients and hormones, for example.

Retention of toxins in key organs may directly impair organ health and function by a number of intracellular mechanisms, including disruption of the sophisticated networks that regulate situational gene expression or the delicate feedbacks by which the intermediates and products of constitutive metabolic chains regulate the activity of key metabolic enzymes.

Eliminating toxins requires certain endogenous substances; for example, catabolism of retinol is accelerated during drug metabolization by the microsomal pathway, thereby contributing to hepatic vitamin A depletion [6]. Nutrients used during metabolic processes of detoxification are concomitantly or subsequently not available for other metabolic processes, thus creating local deficiencies. Chronic exposure may result in systemic deficiencies.

Adipose tissue is a very intricate organ and not merely involved in storing excess calories and “unwanted” compounds. Recent research reveals that hormones released by adipose tissue regulate many bodily functions including emotional state, energy level and body metabolism, hunger and cravings, inflammatory response, and also modulate immune function. Not surprisingly, symptoms associated with disruption of these systems are common in those exposed to environmental chemicals and also in substance abusers [5].

Section snippets

Hypothesis

The 1960s and 1970s were largely focused on the question of whether a diverse collection of synthetic compounds could act as carcinogens, hence, largely ignoring the potential impact of these substances, acting at low levels, to impact other aspects of health, including cognitive behavior and reproductive function [1].

Coincident with new research that reveals accumulations of chemicals in the fat of a very high percentage of human populations [7], the range of adverse effects has expanded

Evidence for drug storage in adipose

As is the case with environmental contaminants, drugs and/or their metabolites – both pharmaceutical and illicit – have the potential to remain in the body for an extended time, contributing to the ongoing accrual of complex mixtures of synthetic compounds [14], [15], [16]. The case of LSD is illustrative in this respect, its long-term adipose accumulation were demonstrated in very early investigations [17]. Research has also shown that cocaine rapidly distributes into the fat tissues following

Drugs impact adipose functions: influence on addictive behaviors

In addition to the possibility that re-release of psychoactive chemicals from adipose may be directly responsible for adverse behavioral and physical health, the potential for adipose-stored chemicals to alter the normal endocrine function of white fat is cause for significant concern. The view of fat as a “storage depot” for the body’s disposition of extra calories – and a “sink” where drugs no longer in circulation are sequestered – changed dramatically in 1994 with the discovery that

Discussion

Various metabolic processes allow organisms to accommodate low doses of foreign compounds. While inherent detoxification pathways result in elimination via the liver and kidneys, and binding proteins effectively remove drugs and toxics from the circulation, these systems do not efficiently eliminate certain compounds and their retention in fat, possibly long-term, is of utmost concern.

There is not a great deal of research that clearly indicates how long drugs and their metabolites remain stored

Conclusions

The contribution of drugs and their metabolites to total toxic burden and resulting adverse health effects cannot be ignored. Simply assessing direct impacts of a drug on a specific unwanted symptom, may overestimate the compound’s real therapeutic index because indirect side-effects, including effects of longer-term adipose-tissue storage are rarely, if ever, assessed. This is akin to the broader economic assessment of environmental impacts of substances such as high-nitrogen fertilizers,

References (92)

  • E. Fride

    The endocannabinoid-CB(1) receptor system in pre- and postnatal life

    Eur J Pharmacol

    (2004)
  • R.S. Ahima

    Central actions of adipocyte hormones

    Trends Endocrinol Metab

    (2005)
  • F. Kiefer et al.

    Leptin: a modulator of alcohol craving?

    Biol Psychiatry

    (2001)
  • A. Kask et al.

    Anorexigenic cocaine- and amphetamine-regulated transcript peptide intensifies fear reactions in rats

    Brain Res

    (2000)
  • W.R. Crowley et al.

    Differential effects of methamphetamine on expression of neuropeptide Y mRNA in hypothalamus and on serum leptin and ghrelin concentrations in ad libitum-fed and schedule-fed rats

    Neuroscience

    (2005)
  • K. Takaya et al.

    Molecular cloning of rat leptin receptor isoform complementary DNAs–identification of a missense mutation in Zucker fatty (fa/fa) rats

    Biochem Biophys Res Commun

    (1996)
  • J. Santos-Alvarez et al.

    Human leptin stimulates proliferation and activation of human circulating monocytes

    Cell Immunol

    (1999)
  • S. Najib et al.

    Human leptin promotes survival of human circulating blood monocytes prone to apoptosis by activation of p42/44 MAPK pathway

    Cell Immunol

    (2002)
  • I.S. Hassan et al.

    A study of the immunology of the chronic fatigue syndrome: correlation of immunologic parameters to health dysfunction

    Clin Immunol Immunopathol

    (1998)
  • C. Martin-Romero et al.

    Human leptin enhances activation and proliferation of human circulating T lymphocytes

    Cell Immunol

    (2000)
  • T. Wenger et al.

    The role of endocannabinoids in the hypothalamic regulation of visceral function

    Prostaglandins Leukot Essent Fatty Acids

    (2002)
  • M.D. Roth et al.

    Effects of delta-9-tetrahydrocannabinol on human immune function and host defense

    Chem Phys Lipids

    (2002)
  • D. Racciatti et al.

    Chronic fatigue syndrome following a toxic exposure

    Sci Total Environ

    (2001)
  • D.W. Schnare et al.

    Evaluation of a detoxification regimen for fat stored xenobiotics

    Med Hypotheses

    (1982)
  • J.G. Barnes

    ‘Sensitivity syndromes’ related to radiation exposures

    Med Hypotheses

    (2001)
  • Environmental Working Group. Body Burden – The Pollution in People; 2003. <www.bodyburden.org> (accessed...
  • W.J. Crinnion

    Environmental medicine, part one: the human burden of environmental toxins and their common health effects

    Altern Med Rev

    (2000)
  • Centers for Disease Control and Prevention (CDC). National Center for Health Statistics (NCHS). National Health and...
  • T. Colborn

    Pesticides – how research has succeeded and failed to translate science into policy: endocrinological effects on wildlife

    Environ Health Perspect

    (1995)
  • C.S. Miller

    Are we on the threshold of a new theory of disease? Toxicant-induced loss of tolerance and its relationship to addiction and abdiction

    Toxicol Ind Health

    (1999)
  • C.S. Lieber

    Microsomal ethanol-oxidizing system

    Enzyme

    (1987)
  • Center for Disease Control and Prevention (CDC). NHANES III Priority Toxicant Reference Range Study Data File Series...
  • T. Colborn

    Environmental estrogens: health implications for humans and wildlife

    Environ Health Perspect

    (1995)
  • K. Yokogawa et al.

    Influence of lipophilicity and lysosomal accumulation on tissue distribution kinetics of basic drugs: a physiologically based pharmacokinetic model

    Meth Find Exp Clin Pharmacol

    (2002)
  • R. Buchert et al.

    Long-term effects of ‘ecstasy’ abuse on the human brain studied by FDG PET

    Nucl Med Commun

    (2001)
  • A. Stoman

    The absorption, distribution, and excretion of drugs and poisons and their metabolites

    (1974)
  • C.N. Chiang et al.

    Implications of drug levels in body fluids: basic concepts

    NIDA Res Monogr

    (1986)
  • J. Axelrod et al.

    The distribution and metabolism of lysergic acid diethylamide

    Ann NY Acad Sci

    (1957)
  • P.K. Nayak et al.

    Physiological disposition and biotransformation of (3H) cocaine in acutely and chronically treated rats

    J Pharmacol Exp Ther

    (1976)
  • E.J. Cone et al.

    Prolonged occurrence of cocaine in human saliva and urine after chronic use

    J Anal Toxicol

    (1989)
  • A.L. Misra et al.

    Persistence of phencyclidine (PCP) and metabolites in brain and adipose tissue and implications for long-lasting behavioural effects

    Res Commun Chem Pathol Pharmacol

    (1979)
  • S.B. Sparber et al.

    A mobilizable pool of d-amphetamine in adipose after daily administration to rats

    Res Commun Chem Pathol Pharmacol

    (1977)
  • M.A. Refaai et al.

    Liver and adipose tissue fatty acid ethyl esters obtained at autopsy are postmortem markers for premortem ethanol intake

    Clin Chem

    (2002)
  • M.A. Refaai et al.

    Ethyl arachidonate is the predominant fatty acid ethyl ester in the brains of alcohol-intoxicated subjects at autopsy

    Lipids

    (2003)
  • J. van Harten

    Clinical pharmacokinetics of selective serotonin reuptake inhibitors

    Clin Pharmacokinet

    (1993)
  • W.A. Daniel et al.

    Contribution of lysosomal trapping to the total tissue uptake of psychotropic drugs

    Pharmacol Toxicol

    (1997)
  • Cited by (11)

    • Conditions associated with fibromyalgia

      2010, Fibromyalgia Syndrome
    • Fragments of the hunt

      2020, Hunter Gatherer Research
    View all citing articles on Scopus

    This manuscript was prepared under the support of private donations to the Foundation for Advancements in Science and Education a 501(c)3 public benefit corporation.

    View full text